Why Clinical Trials Keep Failing Older Patients and How to Fix That
Older adults are the fastest-growing patient group yet remain underrepresented in trials. A new Lancet review maps proven strategies to change that.
Summary
Older patients make up the majority of people treated for serious diseases, yet clinical trials have historically excluded or underrepresented them, leaving doctors with little evidence to guide treatment decisions. A new narrative review in The Lancet synthesizes a decade of recommendations and identifies which strategies have actually worked. Key areas include selecting more representative participants, choosing interventions appropriate for older, often frail individuals, and measuring outcomes that genuinely matter to this population — such as function, quality of life, and independence — rather than endpoints designed for younger adults. The authors highlight successful trial designs that are inclusive, real-world relevant, and complemented by observational data. While uptake of best practices has been slow, the review shows that high-quality, elder-inclusive trials are achievable and provides a practical roadmap for researchers and clinicians.
Detailed Summary
Older adults represent the fastest-growing segment of clinical populations globally, yet they remain systematically underrepresented in the randomized controlled trials that generate most of the evidence guiding medical practice. This mismatch means clinicians regularly extrapolate treatment decisions from data collected in younger, healthier, less medicated, and less frail populations — a scientifically dubious and potentially harmful practice.
This narrative review, published in The Lancet by an international team of geriatric oncologists, geriatricians, and epidemiologists, synthesizes more than a decade of published recommendations aimed at improving trial relevance for older patients. The authors identify three foundational domains: (1) selection and inclusion of truly representative older participants, including those with comorbidities, polypharmacy, and frailty; (2) therapeutic interventions appropriately tailored to older biology and tolerance; and (3) outcome measures that reflect what older patients actually prioritize — functional status, independence, and quality of life rather than surrogate endpoints.
The review acknowledges that uptake of prior recommendations has been frustratingly slow across the research community. However, it highlights several recent examples of trials that have successfully incorporated geriatric assessment, enrolled frail older participants, and used patient-relevant endpoints. These 'existence proofs' demonstrate the approach is feasible.
Observational studies drawing on real-world data sources are identified as a valuable complement to trials, filling evidence gaps where randomized designs are impractical or too slow. Combining these data streams may be essential for advancing geriatric medicine.
From a longevity and healthspan perspective, the implications are significant. Without trials designed for older people, interventions targeting aging-related conditions — cancer, cardiovascular disease, metabolic syndrome, cognitive decline — remain inadequately tested in the very population that bears the greatest disease burden. Rectifying this gap is essential to evidence-based longevity medicine.
Key Findings
- Older patients are the fastest-growing clinical group yet remain underrepresented in trials generating treatment evidence.
- Key gaps involve participant selection, intervention appropriateness, and outcome measures relevant to older adults.
- Successful elder-inclusive trial designs now exist, proving the approach is feasible despite slow industry uptake.
- Observational real-world data can complement trials to fill critical evidence gaps in geriatric populations.
- Outcomes should prioritize function, independence, and quality of life over surrogate endpoints optimized for younger patients.
Methodology
This is a narrative review published in The Lancet synthesizing published literature and recommendations from the past decade on clinical trial design for older patients. It draws on examples of both successful and unsuccessful implementation strategies across multiple disease areas. No formal systematic search or meta-analytic methods are described in the abstract.
Study Limitations
The summary is based on the abstract only, as the full text is not open access; specific trial examples and detailed methodological recommendations cannot be assessed. As a narrative rather than systematic review, it may be subject to selection bias in the literature it highlights. Conflicts of interest declared by several authors include institutional funding from major pharmaceutical companies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: